BioSpace News Archive

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 2020 financial results after the market closes on Monday, November 16, 2020. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on t

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to eval

SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced today the company has signed an agreement with the global life science venture capital firm LifeSci Venture Partners to collaborate on open innovation through a fund

Walgreens Boots Alliance, Inc. announced that Alex Gourlay, co-chief operating officer, and James Kehoe, executive vice president and global chief financial officer, will participate at the 2nd Annual Wolfe Research Healthcare Conference on Thursday, Nov. 19 at 1:10 p.m. Eastern time.

Konica Minolta Healthcare Americas, Inc., announced that SimonMed Imaging, one of the largest medical imaging providers and radiology practices in the US, has partnered with the company to successfully integrate Exa RIS throughout its centers nationwide.

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the Company will present a business and f

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today receipt of written feedback from the U.S. Food and Drug Administration (FDA) that is in general agreement with the Company’s planned clinical trial for Brilacidin, a defensin-mimetic drug candidate, for the treatment of COVID-19. The FDA response completes the Pre-Investigational New Drug (Pre-IND) process. The FDA provided f

In a case study released October 23 by Oculus for Business from Facebook, Nimbus Therapeutics explains why they expect to save tens of thousands of dollars per year by investing in virtual reality (VR) hardware from Oculus and software from Nanome, Inc., and how the technology could potentially help increase their earnings by accelerating their timeline to market.

The Urology Care Foundation, the official Foundation of the American Urological Association, is drawing on the month of November to help break the stigma surrounding bladder health issues and to offer the resources to raise awareness and help start the conversation between a patient and their healthcare provider.

miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management, and the Puerto Rico Health Insurance Administration (“ASES”) announced today the signing of a cooperation agreement aimed at evaluating the clinical and economic utility of the miR Sentinel™ PCC4 Assay (miR Sentinel™ Prostate Test) and its potential impact in Puerto Rico.